Skip to main content
. 2021 Jul 3;69:103457. doi: 10.1016/j.ebiom.2021.103457

Fig. 6.

Fig. 6

The effects of combined HDACi and Dasatinib on SCLC cells. A, Flow cytometry-based analyses of apoptosis (Annexin V positive cells; left) and lipid reactive oxygen species (ROS; right) assayed on SCLC cells (GLC-15) treated for 48h with Dasatinib (0.5 μM) and Vorinostat (HDACi; 1 μM), alone or in combination. The corresponding quantifications (n=3) were shown on the right. *p < 0.05, **p < 0.01, ****p < 0.0001 by ANOVA test. NS, non-significance. B, Small–cell lung cancer (SCLC) cells (GLC-15) were treated for 72h with combined Vorinostat (HDACi; 1 μM) and Dasatinib (0.5 μM) with or without 2.5 mM N-acetyl-L-cysteine (NAC). Cells were seeded 1,000 cells per well in 96-well plates. ****p < 0.0001 (n=3) by ANOVA test. NS, non-significance. C, Flow cytometry-based analyses of apoptosis (Annexin V positive cells; left) and lipid reactive oxygen species (ROS; right) assayed on SCLC cells (GLC-15) treated for 24h with Dasatinib (0.5 μM) and Vorinostat (HDACi; 1 μM), alone or in combination. The assay was repeated twice.